Information Provided By:
Fly News Breaks for November 30, 2015
IDRA
Nov 30, 2015 | 06:24 EDT
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Idera Pharmaceuticals ahead of the company's Phase I/II data on IMO-8400 in Waldenstrom's lymphoma this Saturday, December 5 at the American Society of Hematology meeting. IMO-8400 could provide a safe combination in MyD-88 mutant B-cell lymphoma to extend Imbruvica duration of response, Tenthoff tells investors in a research note. He expects the data to serve as the primary near-term driver for Idera. The analyst has a $7 price target for the shares.
News For IDRA From the Last 2 Days
There are no results for your query IDRA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.